Publication: Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Loading...
Identifiers
Date
2021-02-25
Authors
González Astorga, B
Salvà Ballabrera, F
Aranda Aguilar, E
Élez Fernández, E
García-Alfonso, P
González Flores, E
Vera García, R
Fernández Montes, A
López Muñoz, A M
Salud Salvia, A
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient's profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
Description
MeSH Terms
Age Factors
Angiogenesis Inhibitors
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Camptothecin
Clinical Trials, Phase III as Topic
Colorectal Neoplasms
Drug Substitution
Fluorouracil
Genes, ras
Humans
Leucovorin
Liver Neoplasms
Lung Neoplasms
Mutation
Neovascularization, Pathologic
Organoplatinum Compounds
Proto-Oncogene Proteins B-raf
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Vascular Endothelial Growth Factor A
Angiogenesis Inhibitors
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Camptothecin
Clinical Trials, Phase III as Topic
Colorectal Neoplasms
Drug Substitution
Fluorouracil
Genes, ras
Humans
Leucovorin
Liver Neoplasms
Lung Neoplasms
Mutation
Neovascularization, Pathologic
Organoplatinum Compounds
Proto-Oncogene Proteins B-raf
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Vascular Endothelial Growth Factor A
DeCS Terms
CIE Terms
Keywords
Aflibercept, BRAF, Colorectal cancer, Metastatic, Mutation, Patient profile, Patient selection, RAS, Treatment